Quantcast
Last updated on April 16, 2014 at 6:17 EDT

Latest AMD Stories

2013-11-21 08:27:15

Many leading causes of adult-onset vision loss can be prevented TORONTO, Nov. 21, 2013 /CNW/ - According to the World Health Organization, 75 per cent of vision loss can be prevented or treated.(i) Today CNIB is launching a national campaign called "Worth a thousand words: Preserve your vision" to raise awareness of the impact of adult-onset vision loss and that many conditions are preventable if diagnosed and treated at an early stage. The campaign features a unique photo...

2013-10-30 23:26:30

Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, reports on a recent study revealing a new topical treatment to treat vision loss caused by macular generation. Toronto, ON (PRWEB) October 30, 2013 Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, reports on a recent study revealing a new topical treatment to treat vision loss caused by macular generation. As Bel Marra Health reports in...

2013-10-29 08:24:23

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, October 29, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Intel Corporation (NASDAQ: INTC), NXP Semiconductors N.V. (NASDAQ: NXPI), Advanced Micro Devices, Inc. (NYSE: AMD), Avago Technologies Limited (NASDAQ: AVGO), and Maxim Integrated Products, Inc. (NASDAQ: MXIM). Today's readers may access these reports free of charge - including full price...

2013-10-10 10:27:13

New study reports successful use in mice; implications for both forms of AMD Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration (AMD) in a study of mice that shows promise for clinical use. The research findings, published today in PLOS ONE, are the first to report successful topical use of a compound capable of inhibiting symptoms associated with both...

2013-09-30 23:18:02

National Optometrist Group Offers Macular Degeneration Sufferers Solutions Which Allow Patients to Drive Cars and Pursue Normal Activities Again Corona, CA (PRWEB) September 30, 2013 While a diagnosis of Age Related Macular Degeneration (AMD) can be devastating, it does not mean that all patients will be relegated to a life spent unable to travel far from home. Members of the International Academy of Low Vision Specialists suggest patients get a second opinion, because there are things...

2013-09-27 08:26:07

HAMBURG, Germany, Sept. 27, 2013 /PRNewswire/ -- The Angiogenesis Foundation released a white paper at the 13(th) Euretina Congress that addresses the barriers faced by individuals worldwide in obtaining optimal care for wet age-related macular degeneration (wet AMD). Wet AMD is the most common form of blindness in people 50 years or older in developed nations. The white paper, "Advocating for the Improved Treatment and Outcomes for Wet Age-Related Macular Degeneration," is the result...

2013-09-25 23:27:59

Micro Servers Market Report describes the applications mapping of the market with respect to the growth potential and adoption by the users. http://www.marketsandmarkets.com/Market-Reports/micro-servers-market-952.html (PRWEB) September 25, 2013 According to a new market research report, "Global Micro Servers Market (2013 - 2018), By Processor Type (Intel, Arm, Amd), Component (Hardware, Software, Operating System), Application (Media Storage, Data Centers, Analytics, Cloud...

2013-09-25 08:29:22

Humanized Antibody for Orphan & Non-Orphan Ocular Disorders CLEVELAND, Sept. 25, 2013 /PRNewswire-USNewswire/ -- Today NovelMed Therapeutics announced preclinical study results for its lead compound in two models of AMD, a major cause of blindness affecting more than 2 million people in the United States. (Logo: http://photos.prnewswire.com/prnh/20130909/DC73243LOGO) Two independent preclinical investigations demonstrated that NovelMed's lead compound, an alternative pathway...

2013-09-17 16:23:57

TARRYTOWN, N.Y., Sept. 17, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed results from the Phase 3 VIVID and VISTA trials of EYLEA(®) (aflibercept) Injection in Diabetic Macular Edema (DME) will be presented at an oral session during the upcoming annual meeting of the Retina Society to be held September 26-29 in Los Angeles, United States. These data will be presented on Friday, September 27, at 4:51 PM PDT. Separately, these data...

2013-09-17 08:30:59

SARATOGA, Calif., Sept. 17, 2013 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc. ("VisionCare"), the developer, manufacturer and marketer of the Implantable Miniature Telescope ("IMT" by Dr. Isaac Lipshitz), the only FDA-approved surgical device for end-stage Age-Related Macular Degeneration ("AMD"), announced that it has secured up to $15 Million in long-term, non-dilutive financing to accelerate the commercialization of its novel therapy. The capital was raised exclusively...